RALEIGH, N.C.--(BUSINESS WIRE)--LipoScience, Inc., an in vitro diagnostic company advancing patient care by developing high value proprietary clinical diagnostic tests using nuclear magnetic resonance (NMR) technology, today announced results from a clinical study demonstrating that patients with normal levels of lipoprotein(a) may retain significant risk of atherosclerosis due to an elevated low density lipoprotein particle (LDL-P) number. Lipoprotein(a) is considered a risk factor for atherosclerotic diseases such as coronary heart disease and stroke.
